147 related articles for article (PubMed ID: 15072610)
1. 45th Annual Meeting of the American Society of Hematology December 6-9, 2003.
Gibson AD; Klem J; Price N; Reddy GK
Clin Lymphoma; 2004 Mar; 4(4):206-12. PubMed ID: 15072610
[No Abstract] [Full Text] [Related]
2. Lenalidomide and chronic lymphocytic leukemia.
González-Rodríguez AP; Payer AR; Acebes-Huerta A; Huergo-Zapico L; Villa-Alvarez M; Gonzalez-García E; Gonzalez S
Biomed Res Int; 2013; 2013():932010. PubMed ID: 24163824
[TBL] [Abstract][Full Text] [Related]
3. 45th annual meeting of the American Society of Hematology. December 6-9, 2003, San Diego, California.
Clin Lymphoma; 2003 Dec; 4(3):141-8. PubMed ID: 14715094
[No Abstract] [Full Text] [Related]
4. Highlights from the 46 th annual meeting of the American Society of Hematology.
Fassas A; Barlogie B; Feusner J; Kay NE; Wingard JR
Clin Adv Hematol Oncol; 2005 Feb; 3(2):111-6. PubMed ID: 16166978
[No Abstract] [Full Text] [Related]
5. 37th Annual American Society of Clinical Oncology Meeting. San Francisco, CA. May 12-15, 2001.
D'Orazio AI
Clin Lymphoma; 2001 Jun; 2(1):11-7. PubMed ID: 11712543
[No Abstract] [Full Text] [Related]
6. Lenalidomide for the treatment of B-cell malignancies.
Chanan-Khan AA; Cheson BD
J Clin Oncol; 2008 Mar; 26(9):1544-52. PubMed ID: 18285605
[TBL] [Abstract][Full Text] [Related]
7. The 51st annual meeting of the American Society of Hematology.
Cunningham S; Muneer S; Ranganathan A; Shrader M
Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):11-20. PubMed ID: 20223725
[No Abstract] [Full Text] [Related]
8. New agents for the treatment of genetically high-risk chronic lymphocytic leukemia.
Bazargan A; Tam CS
Leuk Lymphoma; 2010 Jan; 51(1):3-4. PubMed ID: 20001866
[No Abstract] [Full Text] [Related]
9. Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy.
Kahl BS; Cheson BD; Friedberg JW
Clin Adv Hematol Oncol; 2010 May; 8(5):1-16. PubMed ID: 20712081
[TBL] [Abstract][Full Text] [Related]
10. Meeting highlights from: 47th Annual Meeting of the American Society of Hematology December 2005, Atlanta, GA.
Clin Lymphoma Myeloma; 2006 May; 6(6):448-54. PubMed ID: 16796774
[No Abstract] [Full Text] [Related]
11. 50th ASH Annual Meeting.
Fricker J
Lancet Oncol; 2009 Jan; 10(1):19. PubMed ID: 19115516
[No Abstract] [Full Text] [Related]
12. 6th European Hematology Association Meeting. Frankfurt, Germany. June 21-24, 2001.
Maung K; D'Orazio AI
Clin Lymphoma; 2001 Sep; 2(2):74-9. PubMed ID: 11712544
[No Abstract] [Full Text] [Related]
13. Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs).
Wiernik PH
Curr Treat Options Oncol; 2009 Apr; 10(1-2):1-15. PubMed ID: 19016330
[TBL] [Abstract][Full Text] [Related]
14. Rituximab-lenalidomide-dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma.
Ivanov V; Tabouret E; Chuto G; Chetaille B; Fezoui H; Coso D; Rey J; Aurran-Schleinitz T; Schiano JM; Stoppa AM; Blaise D; Bouabdallah R
Leuk Lymphoma; 2010 Sep; 51(9):1758-60. PubMed ID: 20629527
[No Abstract] [Full Text] [Related]
15. Clinical Roundtable Monograph: recent advances in NHL. Highlights from the 51st ASH Annual Meeting and Exposition, December 5-8, 2009, New Orleans, Louisiana.
Czuczman MS; Rummel MJ
Clin Adv Hematol Oncol; 2010 Feb; 8(2):A1-11. PubMed ID: 20391648
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide in lymphomas and chronic lymphocytic leukemia.
Wiernik PH
Expert Opin Pharmacother; 2013 Mar; 14(4):475-88. PubMed ID: 23356486
[TBL] [Abstract][Full Text] [Related]
17. The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia.
Del Poeta G; Del Principe MI; Consalvo MA; Maurillo L; Buccisano F; Venditti A; Mazzone C; Bruno A; Gianní L; Capelli G; Lo Coco F; Cantonetti M; Gattei V; Amadori S
Cancer; 2005 Dec; 104(12):2743-52. PubMed ID: 16284990
[TBL] [Abstract][Full Text] [Related]
18. The 50th Annual Meeting of the American Society of Hematology.
Cunningham S; Muneer S
Clin Lymphoma Myeloma; 2009 Jun; 9(3):197-205. PubMed ID: 19525188
[No Abstract] [Full Text] [Related]
19. Report from the 34th annual meeting of the American Society of Hematology, December 4-8, 1992.
Markman M
J Cancer Res Clin Oncol; 1993; 119(11):695-6. PubMed ID: 8349726
[No Abstract] [Full Text] [Related]
20. A prospective, open-label safety and efficacy study of combination treatment with melphalan, arsenic trioxide, and ascorbic acid in patients with relapsed or refractory multiple myeloma.
Berenson JR; Swift RA; Ferretti D; Purner MB
Clin Lymphoma; 2004 Sep; 5(2):130-4. PubMed ID: 15453931
[No Abstract] [Full Text] [Related]
[Next] [New Search]
